Management of recurrent desmoid tumor after surgery and radiation: Role of cytotoxic and non-cytotoxic therapies

Surgical Oncology

Volumn 8, Issue 4, 1999, Pages 191-196

  Samuels, Brian L ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b ADVOCATE LUTHERAN GENERAL HOSPITAL   (United States)

Author keywords

Biologic therapy; Chemotherapy; Desmoid; Drug therapy; Tamoxifen

Indexed keywords

ANTINEOPLASTIC AGENT; COLCHICINE; DACARBAZINE; DOXORUBICIN; INTERFERON; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; TAMOXIFEN; VINBLASTINE;

ADULT; ARM AMPUTATION; ARM MOVEMENT; CANCER RADIOTHERAPY; CASE REPORT; CYTOTOXICITY; DESMOID TUMOR; FEMALE; HUMAN; LIMB PERFUSION; MOTOR ACTIVITY; PRIORITY JOURNAL; REVIEW; TUMOR RECURRENCE;

ADULT; COMBINED MODALITY THERAPY; FEMALE; FIBROMATOSIS, AGGRESSIVE; FOREARM; HUMANS;

EID: 0033749537     PISSN: 09607404     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-7404(00)00031-1     Document Type: Short Survey

References (42)

1. Pediatric desmoid tumor: Retrospective analysis of 63 cases
2. Local control of extraabdominal desmoid tumors
3. The enigma of desmoid tumors
4. Brachytherapy and function-saving resection of soft tissue sarcoma arising in the limb
5. Desmoids in familial adenomatous polyposis
6. Noncytotoxic drug therapy in children with unresectable desmoid tumors
7. Remission of rapidly growing desmoid tumors after tamoxifen therapy
8. Estrogen and anti-estrogen binding sites in desmoid tumors
9. The desmoid tumor. III. A biochemical and genetic analysis
10. Modification of growth of desmoid tumours in tissue culture by anti-oestrogenic substances: A preliminary report
11. Sequential treatment of recurrent mesenteric desmoid tumor
12. Management of desmoid tumors including a case report of toremifene
13. Colchicine therapy for palmar fibromatosis New England
14. Clinical and cellular effects of colchicine in fibromatosis
15. The management of desmoid tumors
16. Regression of a great abdominal desmoid tumor by interferon alpha
17. Interferon-induced remission in aggressive fibromatosis of the lower extremity
18. Desmoid fibromatosis is a clonal process
19. Aggressive fibromatosis (desmoid tumor) is a monoclonal disorder
20. Increased beta-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors) is a monoclonal disorder
21. Adenomatous polyposis coli gene mutation alters proliferation through its beta-catenin-regulatory function aggressive fibromatosis (desmoid tumor)
22. Frequent mutations in the beta-catenin gene in desmoid tumors from patients without familial adenomatous polyposis
23. Low dose chemotherapy of desmoid tumors
24. Long term follow-up of chemotherapy of desmoid tumors and fibromatosis
25. Combination chemotherapy using vinblastine and methotrexate for the treatment of progressive desmoid tumor in children
26. Chemotherapy in fibromatoses of childhood and adolescence: Results from the Cooperative Soft Tissue Sarcoma Study (CWS) and the Italian Cooperative Study Group (ICG-AIEOP)
27. Therapy of desmoid tumors and fibromatosis using vinorelbine
28. Combination chemotherapy in adult desmoid tumors
29. Use of doxorubicin and dacarbazine for the management of unresectable intra-abdominal desmoid tumors in Gardner's syndrome
30. Chemotherapy for desmoid tumors in association with familial adenomatous polyposis
31. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced tissue and bone sarcomas
32. Gemcitabine in pretreated patients with advanced soft tissue sarcomas - Preliminary results from a phase II trial
33. Gemcitabine in patients with sarcoma of soft tissue or bone resistant to standard chemotherapy
34. Preliminary results of a two-arm phase 2 trial of gemcitabine in patients with gastrointestinal leiomyosarcomas and other soft-tissue sarcomas
35. A Randomised Phase II Trial of Caelyx®/Doxil® versus doxorubicin in advanced or metastatic soft tissue sarcomas - An EORTC soft tissue and bone sarcoma group (STBSG) trial
36. Liposomal doxorubicin (Caelyx®) in advanced soft tissue Sarcoma patients. A phase II study of the Spanish group for research on sarcomas (GEIS)
37. A phase II trial of pegylated liposomal doxorubicin (DOXIL(TM)) demonstrates activity in refractory sarcoma, mesothelioma, and head and neck cancer
38. Cancer research campaign phase II trial of temozolomide in metastatic melanoma
39. High dose tumor necrosis factor-α and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation
40. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
41. Desmoid tumor: The risk of recurrent or new disease with subsequent pregnancy
42. Surgery, desmoid tumors, and familial adenomatous polyposis: Case report and literature review